D Bagdas1,2, D Ergun1, A Jackson1, W Toma1, M K Schulte3, M I Damaj1. 1. Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, USA. 2. Experimental Animals Breeding and Research Center, Faculty of Medicine, Uludag University, Bursa, Turkey. 3. Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, USA.
Abstract
BACKGROUND: Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels. The α4β2 subtype of nAChRs plays an important role in the mediation of pain and several nicotine-evoked responses. Agonists and partial agonists of α4β2 nAChRs show efficacy in animal pain models. In addition, the antinociceptive properties of nicotine, a non-selective nAChR agonist with a high affinity for α4β2 nAChRs, is well-known. There is a growing body of evidence pointing to allosteric modulation of nAChRs as an alternative treatment strategy in experimental pain. Desformylflustrabromine (dFBr) is a positive allosteric modulator (PAM) at α4β2 nAChRs that enhances agonist responses without activating receptors. We hypothesized that dFBr may enhance nicotine-induced antinociception. METHODS: The present study investigated whether dFBr could attenuate mouse chronic constriction injury (CCI)-induced neuropathic pain by increasing endogenous cholinergic tone or potentiating the nicotine-evoked antiallodynic response. RESULTS: We found that subcutaneous administration of dFBr failed to reduce pain behaviour on its own. However, the combination of dFBr with nicotine significantly reversed neuropathic pain behaviour dose- and time-dependently without motor impairment. Our data revealed that this effect was mediated by the α4β2 nAChRs by using competitive α4β2 antagonist dihydro-β-erythroidine. In addition, dFBr failed to potentiate the antiallodynic effect of morphine, which shows the effect of dFBr is unique to α4β2 nAChRs. CONCLUSIONS: The present results suggest that allosteric modulation of α4β2 nAChR may provide new strategies in chronic neuropathic pain. SIGNIFICANCE: α4β2 nAChRs are involved in pain modulation. dFBr, a PAM at α4β2 nAChRs, potentiates the nicotine response dose-dependently in neuropathic pain. Thus, the present results suggest that allosteric modulation of α4β2* nAChR may provide new strategies in chronic neuropathic pain.
BACKGROUND: Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels. The α4β2 subtype of nAChRs plays an important role in the mediation of pain and several nicotine-evoked responses. Agonists and partial agonists of α4β2 nAChRs show efficacy in animal pain models. In addition, the antinociceptive properties of nicotine, a non-selective nAChR agonist with a high affinity for α4β2 nAChRs, is well-known. There is a growing body of evidence pointing to allosteric modulation of nAChRs as an alternative treatment strategy in experimental pain. Desformylflustrabromine (dFBr) is a positive allosteric modulator (PAM) at α4β2 nAChRs that enhances agonist responses without activating receptors. We hypothesized that dFBr may enhance nicotine-induced antinociception. METHODS: The present study investigated whether dFBr could attenuate mouse chronic constriction injury (CCI)-induced neuropathic pain by increasing endogenous cholinergic tone or potentiating the nicotine-evoked antiallodynic response. RESULTS: We found that subcutaneous administration of dFBr failed to reduce pain behaviour on its own. However, the combination of dFBr with nicotine significantly reversed neuropathic pain behaviour dose- and time-dependently without motor impairment. Our data revealed that this effect was mediated by the α4β2 nAChRs by using competitive α4β2 antagonist dihydro-β-erythroidine. In addition, dFBr failed to potentiate the antiallodynic effect of morphine, which shows the effect of dFBr is unique to α4β2 nAChRs. CONCLUSIONS: The present results suggest that allosteric modulation of α4β2 nAChR may provide new strategies in chronic neuropathic pain. SIGNIFICANCE: α4β2 nAChRs are involved in pain modulation. dFBr, a PAM at α4β2 nAChRs, potentiates the nicotine response dose-dependently in neuropathic pain. Thus, the present results suggest that allosteric modulation of α4β2* nAChR may provide new strategies in chronic neuropathic pain.
Authors: S Lauren Kyte; Wisam Toma; Deniz Bagdas; Julie A Meade; Lesley D Schurman; Aron H Lichtman; Zhi-Jian Chen; Egidio Del Fabbro; Xianjun Fang; John W Bigbee; M Imad Damaj; David A Gewirtz Journal: J Pharmacol Exp Ther Date: 2017-10-17 Impact factor: 4.030
Authors: Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj Journal: Neuropharmacology Date: 2021-04-18 Impact factor: 5.273
Authors: Farah Deba; Kara Ramos; Matthew Vannoy; Kemburli Munoz; Lois S Akinola; M Imad Damaj; Ayman K Hamouda Journal: Molecules Date: 2020-06-25 Impact factor: 4.411